|
Market Closed -
Nasdaq
16:00:00 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 1.310 USD | -2.24% |
|
-10.27% | -4.38% |
Company Valuation: Allogene Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,126 | 907.1 | 540.2 | 446.6 | 307.9 | 452.6 | - | - |
| Change | - | -57.34% | -40.45% | -17.32% | -31.06% | 47% | - | - |
| Enterprise Value (EV) 1 | 1,317 | 330.6 | 91.47 | 234.8 | 347 | 256.1 | 302.4 | 121.5 |
| Change | - | -74.89% | -72.33% | 156.69% | 47.8% | -26.21% | 18.1% | -59.83% |
| P/E | -7.89x | -2.71x | -1.54x | -1.61x | -1.57x | -2.17x | -2.04x | -2.34x |
| PBR | 2.32x | 1.36x | 1.06x | 1.07x | 1.07x | 1.13x | 2.27x | 1.02x |
| PEG | - | -0.1x | 0.16x | 0x | 0x | 0.1x | -0.32x | 0.2x |
| Capitalization / Revenue | 55.2x | 3,733x | 5,686x | 20,300x | - | 133x | 37.4x | 5.35x |
| EV / Revenue | 34.2x | 1,361x | 963x | 10,673x | - | 75.3x | 25x | 1.44x |
| EV / EBITDA | -5.37x | -1.03x | -0.29x | -0.96x | -1.76x | -1.28x | -1.26x | -0.45x |
| EV / EBIT | -5.15x | -0.99x | -0.28x | -0.91x | -1.66x | -1.29x | -1.3x | -0.56x |
| EV / FCF | -6.38x | -1.46x | -0.38x | -1.17x | -2.32x | -2.03x | -2.07x | -0.97x |
| FCF Yield | -15.7% | -68.3% | -262% | -85.6% | -43.1% | -49.3% | -48.3% | -103% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.89 | -2.32 | -2.09 | -1.32 | -0.87 | -0.6036 | -0.642 | -0.5596 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.49 | 0.243 | 0.095 | 0.022 | - | 3.4 | 12.09 | 84.64 |
| EBITDA 1 | -245.3 | -321.2 | -313.5 | -243.8 | -197 | -200.2 | -239.7 | -271.5 |
| EBIT 1 | -255.8 | -335.4 | -327.7 | -257.5 | -209.3 | -199.1 | -232.9 | -218.3 |
| Net income 1 | -257 | -332.6 | -327.3 | -257.6 | -190.9 | -185.1 | -219.8 | -212.4 |
| Net Debt 1 | -809.5 | -576.5 | -448.7 | -211.8 | 39.16 | -196.5 | -150.2 | -331.1 |
| Reference price 2 | 14.920 | 6.290 | 3.210 | 2.130 | 1.370 | 1.310 | 1.310 | 1.310 |
| Nbr of stocks (in thousands) | 142,516 | 144,210 | 168,277 | 209,672 | 224,730 | 345,491 | - | - |
| Announcement Date | 2/23/22 | 2/28/23 | 3/14/24 | 3/13/25 | 3/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.17x | 75.31x | -1.28x | -.--% | 453M | |
| 18.75x | 6.69x | 13.41x | 1.58% | 65B | |
| 27.56x | 7.53x | 23.83x | 0.05% | 51.19B | |
| 35.3x | 6.27x | 18.74x | 0.92% | 51.2B | |
| 34.01x | 3.32x | 14.33x | -.--% | 43.93B | |
| 48.9x | 5.59x | 30.73x | -.--% | 41.96B | |
| -18.47x | 189.62x | -19.51x | -.--% | 38.14B | |
| 28.97x | 8.21x | 21.25x | 0.37% | 33.24B | |
| 29.19x | 6.17x | 16.01x | -.--% | 25.2B | |
| -13.23x | 4.78x | -5.79x | -.--% | 22.03B | |
| Average | 18.88x | 31.35x | 11.17x | 0.29% | 37.24B | |
| Weighted average by Cap. | 23.32x | 25.04x | 13.99x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALLO Stock
- Valuation Allogene Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
